Back to Search
STEVEN DEEKS, MD
MD
Internal Medicine Physician
NPI: 1073604666Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
G73895(CA)
Clinical Trials (3)
3
Linked Trials
0
Recruiting
2
With Results
Raltegravir Intensification in HIV-infected Patients
NCT00631449COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR
Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure
NCT00735072COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR
Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance
NCT00187551COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR
Research & Publications (20)
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.
PMID 23589670·Blood·2013
2-rct
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.
PMID 21402547·J Infect Dis·2011
2-rct
HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity.
PMID 19171560·BMJ·2009
6-review
Protease inhibitors as immunomodulatory drugs for HIV infection.
PMID 17700590·Clin Pharmacol Ther·2007
8-other
Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy.
PMID 17892849·Immunity·2007
6-review
Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
PMID 17205477·J Infect Dis·2007
3-trial
Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.
PMID 16731954·J Virol·2006
4-observational
Challenges of developing R5 inhibitors in antiretroviral naive HIV-infected patients.
PMID 16517257·Lancet·2006
7-preclinical
Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection.
PMID 16206068·J Infect Dis·2005
3-trial
Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1.
PMID 14722897·J Infect Dis·2004
8-other
Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load.
PMID 15117761·Blood·2004
8-other
The immune response to AIDS virus infection: good, bad, or both?
PMID 15067312·J Clin Invest·2004
8-other
Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response.
PMID 12556690·AIDS·2003
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 995 POTRERO AVENUE, BLDG 80 WARD 84
SAN FRANCISCO, CA 94110 - Phone
- (415) 476-4082
Quick Facts
- NPI
- 1073604666
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Clinical Trials
- 3
- Publications
- 20
Are you this provider?
Claim Your Profile